LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Harvard Bioscience Inc

Geschlossen

BrancheGesundheitswesen

0.73 -3.95

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.72

Max

0.76

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.1M

-1.2M

Verkäufe

141K

21M

Gewinnspanne

-5.978

Angestellte

330

EBITDA

1M

1.2M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+163.16% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

8.2M

34M

Vorheriger Eröffnungskurs

4.68

Vorheriger Schlusskurs

0.73

Nachrichtenstimmung

By Acuity

26%

74%

84 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Harvard Bioscience Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Dez. 2025, 22:02 UTC

Ergebnisse

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10. Dez. 2025, 21:46 UTC

Ergebnisse

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10. Dez. 2025, 23:52 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10. Dez. 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10. Dez. 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10. Dez. 2025, 23:20 UTC

Ergebnisse

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10. Dez. 2025, 23:15 UTC

Ergebnisse

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10. Dez. 2025, 22:59 UTC

Market Talk
Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10. Dez. 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10. Dez. 2025, 22:40 UTC

Ergebnisse

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. Dez. 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. Dez. 2025, 22:06 UTC

Ergebnisse

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. Dez. 2025, 22:02 UTC

Ergebnisse

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. Dez. 2025, 22:00 UTC

Ergebnisse

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10. Dez. 2025, 21:53 UTC

Ergebnisse

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. Dez. 2025, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10. Dez. 2025, 21:50 UTC

Market Talk
Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

10. Dez. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. Dez. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10. Dez. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. Dez. 2025, 21:33 UTC

Ergebnisse

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10. Dez. 2025, 21:32 UTC

Ergebnisse

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. Dez. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10. Dez. 2025, 21:25 UTC

Ergebnisse

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. Dez. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10. Dez. 2025, 21:16 UTC

Ergebnisse

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10. Dez. 2025, 21:15 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10. Dez. 2025, 21:15 UTC

Ergebnisse

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10. Dez. 2025, 21:14 UTC

Ergebnisse

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10. Dez. 2025, 21:14 UTC

Ergebnisse

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Peer-Vergleich

Kursveränderung

Harvard Bioscience Inc Prognose

Kursziel

By TipRanks

163.16% Vorteil

12-Monats-Prognose

Durchschnitt 2 USD  163.16%

Hoch 2 USD

Tief 2 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Harvard Bioscience Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

0.3 / 0.3401Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

No Evidence

Langfristig

No Evidence

Stimmung

By Acuity

84 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat